Global EditionASIA 中文双语Français
China
Home / China / Health

Healthy authorities approve use of cholesterol drug

By Lin Shujuan | chinadaily.com.cn | Updated: 2023-08-23 13:55
Share
Share - WeChat

China's National Medical Products Administration on Tuesday approved the use of Inclisiran, a cholesterol-lowering small interfering RNA (siRNA), for the treatment of adults with primary hypercholesterolemia (heterozygous familial and non-familial) or mixed dyslipidemia.

Developed by Novartis, Inclisiran is the world's only siRNA medicine for LDL-C reduction and will help make long-term lipid management easier for physicians and patients, said the company.

The European Medicines Agency had in December 2020 approved Inclisiran for use in the treatment of adults with primary hypercholesterolemia or mixed dyslipidemia. The US Food and Drug Administration approved it in December 2021 and expanded its indications to primary hypercholesterolemia patients in July 2023.

Top
BACK TO THE TOP
English
Copyright 1995 - . All rights reserved. The content (including but not limited to text, photo, multimedia information, etc) published in this site belongs to China Daily Information Co (CDIC). Without written authorization from CDIC, such content shall not be republished or used in any form. Note: Browsers with 1024*768 or higher resolution are suggested for this site.
License for publishing multimedia online 0108263

Registration Number: 130349
FOLLOW US